Celeste Boeckman
Nephrology · Oklahoma City, OKNPI 1083903728
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,545 of the $89,585 with a category attached, or 93.3%. Boehringer Ingelheim accounts for 66.3% of it on its own, with 24 other manufacturers making up the rest. Among nephrology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $308.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$59K
- Lilly USA, LLC$27K
- AstraZeneca$802
- Novartis$446
- Amgen$377
- Ardelyx, Inc.$285
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$83,54593%
- Travel & lodging$9281%
- Food & beverage$5,0236%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 103 | $59,368 |
| Lilly USA, LLC | 42 | $26,820 |
| AstraZeneca(2 entities) | 34 | $802 |
| Novartis | 18 | $446 |
| Amgen | 17 | $377 |
| Ardelyx, Inc. | 17 | $285 |
| Fresenius USA Marketing, Inc. | 10 | $204 |
| Vantive US Healthcare LLC | 1 | $149 |
| Bayer | 7 | $140 |
| Travere Therapeutics, Inc. | 6 | $126 |
| Shield Therapeutics Inc | 3 | $112 |
| Aurinia Pharma U.S., Inc. | 2 | $111 |
| ANI Pharmaceuticals, Inc. | 4 | $105 |
| Vifor Pharma, Inc. | 4 | $89 |
| Cormedix Inc. | 4 | $81 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Daiichi Sankyo Inc. | 2 | $45 |
| OPKO Pharmaceuticals, LLC | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Pfizer | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Merck | 1 | $14 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$84,956
- Renal - PD$149
- Tavneos$117
How this compares
$89,585 in reported general payments places this provider in the 95th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 212 | $235,069 |
| FarxigaDapagliflozin Propanediol | 86 | $80,201 |
| KerendiaFinerenone | 46 | $59,947 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $19,924 |
| Sevelamer Carbonate | 34 | $3,178 |
| Calcium Acetate | 18 | $2,054 |
| Nifedipine ErNifedipine | 49 | $1,608 |
| Hydralazine Hcl | 93 | $1,528 |
| Potassium Chloride | 75 | $1,332 |
| Torsemide | 44 | $1,257 |
| Losartan Potassium | 131 | $1,219 |
| Lisinopril | 149 | $1,094 |
| Amlodipine Besylate | 130 | $1,070 |
| Furosemide | 156 | $990 |
| Tamsulosin Hcl | 61 | $618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $59,368 | $235,069212 claims |
| AstraZenecaFarxiga, Lokelma | $802 | $100,125105 claims |
| BayerKerendia | $140 | $59,94746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Oklahoma City
- Joseph GhataOklahoma City$45K
- Benjamin CowleyOklahoma City$36K
- Brad CarterOklahoma City$13K
- Laura RankinOklahoma City$11K
- Gary BondOklahoma City$9K
- Sudhir KhannaOklahoma City$7K
- Jawaid JamalOklahoma City$7K
- Patrick ReevesOklahoma City$6K
- Bradley LongOklahoma City$6K
- Chris SholerOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.